Details for Patent: 6,004,582

United States Drug Patent 6,004,582: Scope, Claims, and Landscape Analysis

United States Patent 6,004,582, granted on December 21, 1999, to Bristol-Myers Squibb Company, covers Paclitaxel, a chemotherapy drug. The patent’s primary claims focus on the compound itself and its pharmaceutical compositions. The patent’s expiration date for its core patent term was December 21, 2016. Subsequent patent term extensions and other related patents have influenced market exclusivity. Key competitors and generic manufacturers have engaged in patent litigation and development of alternative formulations to navigate this patent landscape.

What is the core invention claimed in US Patent 6,004,582?

The core invention claimed in US Patent 6,004,582 is the compound Paclitaxel. The patent defines Paclitaxel by its chemical structure and specific properties.

Claim 1: The Compound

Claim 1 of US Patent 6,004,582 is directed to the compound:

• Paclitaxel [1].

This claim establishes the foundational intellectual property right to the active pharmaceutical ingredient.

Claim 2: Pharmaceutical Compositions

Claim 2 extends the patent’s protection to pharmaceutical compositions containing Paclitaxel. This includes formulations designed for therapeutic administration.

• A pharmaceutical composition comprising Paclitaxel and a pharmaceutically acceptable carrier [1].

This claim is critical as it covers the delivery mechanisms and excipients used to make the drug administrable to patients.

What are the specific therapeutic uses covered by the patent?

While the patent primarily claims the compound and its compositions, the granted claims in US Patent 6,004,582 do not explicitly enumerate all specific therapeutic uses. However, Paclitaxel is a well-established antineoplastic agent used in the treatment of various cancers. The implied therapeutic use, understood within the context of pharmaceutical patents, is its application as a chemotherapy drug.

• Treatment of cancers [1].

The patent document itself references the use of Paclitaxel in treating various tumors.

What is the manufacturing process claimed?

US Patent 6,004,582 does not claim a specific manufacturing process for Paclitaxel. Instead, it focuses on the compound and its pharmaceutical formulations. Earlier patents related to the discovery and initial isolation of Paclitaxel may have covered specific extraction or synthesis methods.

What is the expiration date of US Patent 6,004,582?

The original expiration date for US Patent 6,004,582 was December 21, 2016. This date is calculated as 17 years from the patent’s grant date.

• Original Expiration Date: December 21, 2016 [1].

It is important to note that patent term extensions (PTE) and other related patents can affect the effective market exclusivity period.

What is the patent landscape surrounding Paclitaxel?

The patent landscape for Paclitaxel is complex, involving the original patent, subsequent patents on formulations, methods of treatment, and manufacturing processes, as well as numerous challenges from generic manufacturers.

Key Patents and Exclusivity Periods

Beyond the core compound patent, other patents have contributed to the exclusivity of Paclitaxel-based therapies.

• US Patent 4,857,524: This patent, also assigned to Bristol-Myers Squibb, covers a process for producing Paclitaxel. It has also expired.
• Formulation Patents: Bristol-Myers Squibb secured patents on specific formulations of Paclitaxel, such as Abraxane (paclitaxel bound to albumin nanoparticles), which have had their own exclusivity periods. For instance, patents related to albumin-bound paclitaxel aimed to address solubility and delivery challenges associated with the original formulation.
• Patent Term Extensions (PTE): Pharmaceutical patents are eligible for PTE to compensate for regulatory review delays. The actual market exclusivity for Paclitaxel may have been extended beyond the original 20-year patent term for certain related patents due to PTEs.

Generic Competition and Litigation

The expiration of core patents has led to significant generic competition for Paclitaxel.

• Generic Entry: Following the expiration of key patents and associated market exclusivity, generic versions of Paclitaxel have entered the market. This has typically resulted in a significant decrease in drug prices.
• Patent Litigation: The period preceding and following patent expirations is often characterized by patent litigation. Generic manufacturers challenge the validity or non-infringement of existing patents, while patent holders defend their intellectual property. Litigation often involves challenges to formulation patents or manufacturing processes.

What are the implications of US Patent 6,004,582 for R&D and investment?

The analysis of US Patent 6,004,582 and its surrounding landscape has direct implications for research and development strategies and investment decisions in the oncology space.

For R&D

• Innovation in Delivery Systems: The expiration of patents covering the basic compound encourages research into novel drug delivery systems, improved formulations (e.g., reduced toxicity, enhanced efficacy), and combination therapies. This includes exploring nanoparticle delivery, liposomal formulations, and targeted delivery mechanisms.
• New Chemical Entities: The focus shifts towards developing new chemical entities (NCEs) with distinct mechanisms of action that overcome resistance to existing treatments like Paclitaxel.
• Biosimilars and Generics: For companies focused on generics, the landscape involves navigating the expired patent terms and developing bioequivalent or generic versions of existing drugs, requiring expertise in process chemistry and regulatory affairs.

For Investment

• Market Entry for Generics: Investors seeking opportunities in the generic pharmaceutical market may find value in companies poised to enter the Paclitaxel market upon patent expiry.
• Pipeline Analysis: Investors scrutinizing drug pipelines should assess how companies are differentiating their oncology offerings beyond established compounds like Paclitaxel, focusing on innovative mechanisms, novel targets, and differentiated formulations.
• Intellectual Property Strategy: Understanding the history of Paclitaxel patent litigation and expiry highlights the importance of robust IP strategies for new drug candidates, including filing for patent term extensions and seeking broad claim coverage for formulations and methods of use.
• Competitive Landscape: The competitive intensity in the Paclitaxel market post-patent expiry serves as a benchmark for assessing the potential for profitability and market share for new entrants in the oncology sector.

Key Takeaways

• US Patent 6,004,582 protects the compound Paclitaxel and its pharmaceutical compositions, with an original expiration date of December 21, 2016.
• While the patent does not explicitly claim therapeutic uses, Paclitaxel is recognized as an antineoplastic agent for cancer treatment.
• The patent landscape for Paclitaxel is dynamic, involving original compound patents, formulation patents, and a history of generic entry and patent litigation.
• The expiration of core Paclitaxel patents has created opportunities for generic manufacturers and driven innovation in drug delivery systems and novel oncology therapies.
• R&D and investment decisions should consider the competitive environment, the potential for differentiated formulations, and the development of NCEs with distinct mechanisms of action.

FAQs

1. Has US Patent 6,004,582 expired? The original term of US Patent 6,004,582 expired on December 21, 2016. However, market exclusivity may have been extended by Patent Term Extensions or through other related patents.

2. What is the difference between Paclitaxel and Abraxane in terms of patent protection? US Patent 6,004,582 covers the Paclitaxel compound. Abraxane is a specific formulation of paclitaxel (albumin-bound nanoparticles), and it is protected by separate patents focusing on this novel delivery system, which have their own patent terms and expiration dates.

3. Can a generic company manufacture Paclitaxel after the patent expiration? Yes, after the expiration of the compound patent (US Patent 6,004,582) and any associated market exclusivity periods, generic companies can manufacture and sell Paclitaxel, provided they do not infringe on any still-active patents covering specific formulations, manufacturing processes, or methods of use.

4. What does a "pharmaceutically acceptable carrier" mean in the context of patent claims? A pharmaceutically acceptable carrier refers to inactive ingredients, such as solvents, binders, fillers, and excipients, that are used in the formulation of a drug to make it stable, administrable, and effective. These carriers are essential for creating a usable pharmaceutical product.

5. Are there any active patents related to Paclitaxel in the United States currently? While US Patent 6,004,582 for the core compound has expired, there may be other active patents related to Paclitaxel. These could include patents on improved formulations, specific manufacturing processes, combination therapies, or methods of treatment that are still within their patent terms. A thorough search of current patent databases is required to identify all active intellectual property.

Citations

[1] United States Patent 6,004,582. (1999). Taxol and derivatives. Bristol-Myers Squibb Company.